Results 211 to 220 of about 42,544 (264)

Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients – FINITE study

Journal of Hepatology, 2017
Julian Schulze Zur Wiesch, Markus Cornberg, Thomas Berg   +2 more
exaly   +2 more sources

Development of a protocol for the quantitative determination of HBeAg using the Elecsys^® HBeAg immunoassay

Journal of Viral Hepatitis, 2010
Summary.  Loss of hepatitis ‘e’ antigen (HBeAg) in patients with HBeAg‐positive chronic hepatitis B is associated with improved long‐term clinical outcome and is defined as a goal of antiviral treatment by clinical practice guidelines. Recent studies suggest that baseline levels and on‐treatment monitoring of HBeAg levels may identify patients most ...
Wursthorn, Karsten, Zacher, Behrend, Jaroszewicz, Jerzy, Darnedde, Martina, Manns, Michael, Wedemeyer, Heiner   +5 more
openaire   +2 more sources

High risk of clinical events in untreated HBeAg‐negative chronic hepatitis B patients with high viral load and no significant ALT elevation

Alimentary Pharmacology and Therapeutics, 2019
It remains unknown whether antiviral treatment for HBeAg‐negative chronic hepatitis B (CHB) patients having high viral loads without significant elevation of alanine aminotransferase (ALT) levels would reduce the risks of clinical events.
G. Choi, Gi-Ae Kim, Jonggi Choi, Seungbong Han, Y. Lim   +4 more
semanticscholar   +1 more source

Pretreatment HBeAg level and an early decrease in HBeAg level predict virologic response to entecavir treatment for HBeAg‐positive chronic hepatitis B

Journal of Viral Hepatitis, 2011
Summary.  There are few reports on hepatitis B e antigen (HBeAg) titres during nucleos(t)ide analogues treatment. We investigated the changes in HBeAg levels in patients treated with entecavir and the usefulness of HBeAg quantification for predicting antiviral response.
J H, Kwon, J W, Jang, S, Lee, J, Lee, K W, Chung, Y S, Lee, J Y, Choi   +6 more
openaire   +2 more sources

HBeAg in Viral Hepatitis Type B

Digestion, 2009
58 patients with acute hepatitis type B, including 13 with fulminant hepatitis, were tested on presentation for HBeAg. Positive results were obtained in 24%. The frequency was highest in those with fulminant hepatitis (46% positive), and this was probably related to the earlier presentation of patients with this condition. Patients with acute hepatitis
I L, Woolf, N, El Sheikh, H, Cullens, A L, Eddleston, R, Williams   +4 more
openaire   +2 more sources

Characterization of hbeag by physicochemical and immunochemical methods

Journal of Medical Virology, 1980
AbstractHBeAg, which is a hepatitis B‐associated antigen, was purified and characterized. The end product from ion exchange, gel filtration and immunoadsorbent columns consisted mainly of immunoglobulin G (IgG) molecules, identified by immunoelectrophoresis and polyacrylamide gel electrophoresis.
D, Katz, J L, Melnick, F B, Hollinger
openaire   +2 more sources

Relationship between hepatitis B core‐related antigen levels and sustained HBeAg seroconversion in patients treated with nucleo(s)tide analogues

Journal of Viral Hepatitis, 2019
Hepatitis B e antigen (HBeAg) seroconversion experienced during nucleo(s)tide analogue (NUC) therapy is often not sustained. We aimed to study whether hepatitis B core‐related antigen (HBcrAg) levels predict sustained HBeAg seroconversion in patients ...
André Boonstra, Milan Sonneveld, Margo J H Van Campenhout   +2 more
exaly   +2 more sources

Patients with interferon-induced HBeAg seroconversion have a higher risk of HBV reactivation and HBeAg seroreversion

Hepatology International, 2014
It remains unclear whether chronic hepatitis B patients who undergo interferon (IFN)-induced hepatitis B e antigen (HBeAg) seroconversion have a higher risk of hepatitis B virus (HBV) reactivation and HBeAg seroreversion than those with spontaneous HBeAg seroconversion.A total of 80 and 251 non-cirrhotic patients with interferon-induced and spontaneous
Chien-Hung, Chen, Sheng-Nan, Lu, Chuan-Mo, Lee, Chao-Hung, Hung, Jing-Houng, Wang, Tsung-Hui, Hu   +5 more
openaire   +2 more sources

Increased risk of HCC in HBeAg-negative indeterminate phase compared with HBeAg-negative chronic infection

Hepatology
Background and Aims: The outcomes and benefits of antiviral therapy in patients with indeterminate phase HBeAg-negative chronic hepatitis B are not well described in treatment guidelines. We examined HCC risk among these patients. Approach and Results:
Vicki Wing-Ki Hui, Grace Lai-Hung Wong, Junlong Dai, Yee-Kit Tse, Mandy Sze-Man Lai, Jimmy Che-To Lai, Henry Lik-Yuen Chan, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip   +8 more
openaire   +2 more sources

Predictive Factors for Early HBeAg Seroconversion in Acute Exacerbation of Patients With HBeAg-Positive Chronic Hepatitis B

Gastroenterology, 2009
This study aimed to identify the predictors for early hepatitis B e antigen (HBeAg) seroconversion following acute exacerbation (AE) in patients with HBeAg-positive chronic hepatitis B (CHB).A total of 151 patients with HBeAg-positive CHB and AE were consecutively enrolled. AE was defined as an elevation of alanine aminotransferase level to more than 5
Hyoung Su, Kim, Ha Jung, Kim, Woon Geon, Shin, Kyung Ho, Kim, Jin Heon, Lee, Hak Yang, Kim, Myoung Kuk, Jang   +6 more
openaire   +2 more sources